2. Search Result
Search Result
Results for "

Lipid II inhibitors

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Peptides

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156009
    CDFI

    		Others Infection
    CDFI is an inhibitor of the lipid II flippase MurJ. CDFI potentiates the activity of β-lactams against MRSA .
    CDFI
  • HY-156237
    Beclin1-ATG14L interaction inhibitor 1
    1 Publications Verification

    		 Autophagy Others
    Beclin1-ATG14L interaction inhibitor 1 (com 19) is a selective Beclin1-ATG14L interaction inhibitor. This protein interaction mechanism specifically targets complex I of the lipid kinase VPS34 without affecting complex II. Because the integrity of VPS34 complex II depends on the Beclin 1-UVRAG interaction. Beclin1-ATG14L interaction inhibitor 1 can disrupt the formation of VPS34 complex I and inhibit autophagy, but does not affect complex II-related vesicle transport .
    Beclin1-ATG14L interaction inhibitor 1
  • HY-127146
    Platensimycin

    		Antibiotic Bacterial Infection
    Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.
    Platensimycin
  • HY-117254
    BAS00127538

    		Bacterial Infection
    BAS00127538 is a Lipid II inhibitor with antibacterial activity. As the first small molecule Lipid II inhibitor, BAS00127538 has a structure that is significantly different from compounds that naturally bind to Lipid II, such as vancomycin. The activity of BAS00127538 in terms of cytotoxicity and Lipid II binding is of great significance in antibacterial effects. Studies on BAS00127538 have shown that it has the potential to inhibit infection .
    BAS00127538
  • HY-N12440
    Sarmenoside II

    		Others Others
    Sarmenoside II is a flavonol glycoside with activity that inhibits lipid accumulation. Sarmenoside II inhibits albumin-oleate-induced lipid accumulation in HepG2 cells by approximately 30% at 100 μM.
    Sarmenoside II
  • HY-P0230
    Teixobactin

    		Antibiotic Bacterial Infection
    Teixobactin is a potent antibiotic. Teixobactin shows antibacterial activity for gram-negative bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II and lipid III .
    Teixobactin
  • HY-159483
    SelB-1

    		Topoisomerase Autophagy Glutathione Peroxidase Cancer
    SelB-1 serves as a dual inhibitor for Topoisomerase I/II. SelB-1 possesses anticancer activity and can be utilized in the research of prostate cancer and colon cancer. Furthermore, SelB-1 is also capable of inducing autophagy gene expression and lipid peroxidation, while simultaneously reducing the level of GSH .
    SelB-1
  • HY-179038
    PYO12

    		Bacterial Infection
    PYO12 is a 3-phenyl-4-phenoxypyrazole type antibacterial compound. PYO12 exhibits selective activity against Gram-positive bacteria with MIC for S. aureus, B. subtilis, S. pneumoniae, and MRSA of 1, 1, 1, and 4 μg/mL respectively. PYO12 has no activity against Gram-negative bacteria. PYO12 can significantly increase bacterial membrane permeability and significantly upregulate cell wall stress-related genes, possibly by binding to the C55-PP part of lipid II. PYO12 shows a concentration-dependent bactericidal effect, has low toxicity to mammalian cells, and does not cause hemolysis. PYO12 can be used to develop new antibiotics targeting bacterial cell wall synthesis .
    PYO12
  • HY-P2200
    Siamycin I

    BMY-29304

    		 HIV Antibiotic Infection Inflammation/Immunology
    Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .
    Siamycin I

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: